Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3067% below fair value
$0.39−0.02 (-5.56%)
Close on Nov 19, 2026Market cap $59.81MP/E –Yield –
Coherus Oncology free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Coherus Oncology's free cash flow for the twelve months ending Dec 31, 2023 was -$175.17M. For fiscal 2023 it was -$175.17M. The highest annual figure on record is $146.91M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$175.17M | – |
| FY2022 | Dec 31, 2022 | -$243.16M | – |
| FY2021 | Dec 31, 2021 | -$38.72M | -126.4% |
| FY2020 | Dec 31, 2020 | $146.91M | +453.7% |
| FY2019 | Dec 31, 2019 | $26.53M | – |
| FY2018 | Dec 31, 2018 | -$160.06M | – |
| FY2017 | Dec 31, 2017 | -$204.86M | – |
| FY2016 | Dec 31, 2016 | -$259.06M | – |
| FY2015 | Dec 31, 2015 | -$114.15M | – |
| FY2014 | Dec 31, 2014 | -$26.78M | -277.9% |
| FY2013 | Dec 31, 2013 | $15.05M | – |
| FY2012 | Dec 31, 2012 | -$20.03M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$12.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$54.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$68.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$100.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.55M | -379.2% |
| Q2 FY2022 | Jun 30, 2022 | -$50.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$54.66M | -4573.0% |
| Q4 FY2021 | Dec 31, 2021 | -$52.79M | -264.1% |
| Q3 FY2021 | Sep 30, 2021 | $13.45M | -70.3% |
| Q2 FY2021 | Jun 30, 2021 | -$603.00K | -101.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.22M | -89.6% |
| Q4 FY2020 | Dec 31, 2020 | $32.17M | +85.7% |
| Q3 FY2020 | Sep 30, 2020 | $45.24M | -16.3% |
| Q2 FY2020 | Jun 30, 2020 | $57.81M | +362.6% |
| Q1 FY2020 | Mar 31, 2020 | $11.69M | – |
| Q4 FY2019 | Dec 31, 2019 | $17.32M | – |
| Q3 FY2019 | Sep 30, 2019 | $54.03M | – |
| Q2 FY2019 | Jun 30, 2019 | $12.50M | – |
| Q1 FY2019 | Mar 31, 2019 | -$57.32M | – |
| Q4 FY2018 | Dec 31, 2018 | -$47.58M | – |
| Q3 FY2018 | Sep 30, 2018 | -$43.28M | – |
| Q2 FY2018 | Jun 30, 2018 | -$35.54M | – |
| Q1 FY2018 | Mar 31, 2018 | -$33.67M | – |
| Q4 FY2017 | Dec 31, 2017 | -$30.03M | – |
| Q3 FY2017 | Sep 30, 2017 | -$43.33M | – |
| Q2 FY2017 | Jun 30, 2017 | -$56.54M | – |
| Q1 FY2017 | Mar 31, 2017 | -$74.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$90.46M | – |
| Q3 FY2016 | Sep 30, 2016 | -$62.45M | – |
See a number that looks wrong?